Resumo A doença causada pelo coronavírus (COVID-19), inicialmente descrita em Wuhan, China, foi recentemente declarada pela Organização Mundial da Saúde (OMS) como uma pandemia global. A idade avançada e a presença de comorbilidades, características bem definidas na população portadora de tumores sólidos, foram interpretadas como fatores de risco para doença grave e morte. O estado de imunodepressão relacionado com o cancro e os seus tratamentos associados também parece desempenhar um papel ativo no prognóstico, resposta e resultados clínicos neste tipo de doentes. Apesar dos doentes oncológicos metastizados não serem bons candidatos para o tratamento em Unidade de Cuidados Intensivos (UCI), o prognóstico individual deve ser tido em consideração. Descrevemos um caso de um doente com neoplasia da próstata (CaP) metastizado (estádio IV) infetado pelo SARS-CoV-2, que necessitou de UCI e recuperou da infeção pelo COVID-19.

Abstract The disease caused by coronavirus (COVID-19), initially described in Wuhan, China, was declared by the World Health Organization (WHO) as a global pandemic. The presence of comorbidities, characteristic in the patients with tumors, were interpreted as risk factors for severe disease and increase death rates. The cancer-related immunosuppression status and its associated treatments appear to play an active role in prognosis, response and clinical outcomes in these types of patients. Although metastatic cancer patients are not good runners for management in the Intensive Care Unit (ICU), the individual prognosis must be acquired. We describe all the steps of a challenging clinical case from a patient with metastatic prostate cancer (CaP) infected with coronavirus, whom needed to be admitted to the ICU.

Purpose To evaluate the clinical outcome of a cohort of localized prostate cancer patients treate with 125-I permanent brachytherapy at the São José Hospital – CHLC, Lisbon. Materials and Methods A retrospective analysis was carried out on 429 patients with low and intermediate-risk of prostate adenocarcinoma, according to the recommendations of the EORTC, who underwent 125I brachytherapies in intraoperative dosimetry “real-time” system between September 2003 and September 2013. Results The mean follow-up was 71.98 months. Biochemical relapse of disease by rising PSA (Phoenix criterion) was observed in 18 patients (4.2%). Through the application of Kaplan-Meier survival curves in this sample, the rate of survival at 6 years without biochemical relapse was higher than 95%. By Iog rank test comparing biochemical relapse with initial PSA (15-10 and <10) and Gleason values (7 and <7), there was no statistical difference (P=0.830) of the initial PSA in the probability of developing biochemical relapse. In relation to Gleason score, it was noted a statistical difference (P<0.05), demonstrating that patients with Gleason 7 are more likely to develop biochemical relapse. Conclusions Brachytherapy as monotherapy is at present an effective choice in the treatment of localized prostate adenocarcinoma. Biochemical relapses are minimal. The initial PSA showed no statistically difference in the rate of relapses, unlike the value Gleason, where it was demonstrated that patients with Gleason 7 have a higher probability of biochemical relapse. Cases with PSA bounce should be controlled before starting a salvage treatment.